Multidrug resistant Acinetobacter species infection among neonatal sepsis

Abstract

Background: Neonatal septicemia is regarded as one of the leading causes of mortality as well as morbidity globally. There is emerging evidence that multidrug resistant Acinetobacter baumannii (MDRAB) and mortality are linked in the scientific literature.
Objective: It was the goal of this work to improve the prognosis of neonates with Acinetobacter species through early detection of infection and risk factors associated with increased mortality and effective management.
Patients and Methods: Our study was done on 60 neonates who were suspected to having sepsis at Zagazig University Hospitals, Pediatric Department. All neonatal blood samples were taken aseptically and the bacteria that caused septicemia were identified. Acinetobacter species were identified. Drug sensitivity tests were performed on a variety of risk variables.
Results: Only nine patients had Acinetobacter infection (15% of all patients) and two thirds of them had multi drug resistance (resistant for ≥3 antimicrobials). Gestational age more than or equal 36 weeks was protective factor against getting infection with MDR-Acinetobacter among the studied patients. Acinetobacter was most sensitive to ciprofloxacin and tigecycline antibiotic, while it was most resistant to sulphamethoxazole /trimethoprim antibiotics
Conclusion: Neonatal MDR Acinetobacter septicemia is on the rise, and it's connected with high morbidity as well as mortality rates. There must be an infection control policy in place at every neonatal intensive care unit (NICU) in order to control Acinetobacter infection and enhance outcomes.